 NEW HAVEN, Conn., April 05, 2021 GLOBE NEWSWIRE -- Arvinas, Inc. Nasdaq: ARVN, a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced two upcoming presentations at the American Association for Cancer Research AACR Annual Meeting 2021, which will be held virtually from April 10-15, 2021 and May 17-21, 2021. These presentations will describe the discovery of Arvinas two clinical-stage PROTAC degraders, ARV-110 and ARV-471, including the first disclosures of their structures. 